Silexion Therapeutics Corp
SLXN- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0002022416
No open-market purchases or sales by Silexion Therapeutics Corp insiders were filed in the last 90 days; 6 institutions reported holding it in 13F filings for Q2 2026, worth $42.5K in total; no superinvestor holds it.
Other share classesSLXNW
Q3 2025 vs. Q2 2025
How the institutions holding Silexion Therapeutics Corp changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Q3 2025 | Change |
|---|---|---|---|
| Holders | 8 | 4 | −4 |
| Shares | 318.1K | 5.08K | −313.0K (−98.4%) |
| Value | $258.1K | $17.3K | −$240.8K (−93.3%) |
New holders (2)
Institutions that held Silexion Therapeutics Corp at the end of Q3 2025 but not at the end of Q2 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Montag A & Associates Inc | 3,000 | $10.2K | 0.00% |
| Pflug Koory, LLC | 333 | $1.13K | 0.00% |
Sold out (6)
Institutions that held Silexion Therapeutics Corp at the end of Q2 2025 and filed for Q3 2025 without it.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| Wildcat Capital Management, LLC | 113,428 | $91.9K |
| Meyer Handelman Co | 32,967 | $26.7K |
| Moloney Securities Asset Management, LLC | 20,000 | $16.2K |
| Virtu Financial LLC | 14,264 | $12.0K |
| StoneX Group Inc. | 11,241 | $9.11K |
| Bank of America Corp | 500 | $405 |